The I-TECH study published in JAMA showed that high-dose ivermectin cannot prevent patients from developing severe COVID-19!
Take a look at the peer-reviewed study, and find out why ivermectin really is useless against COVID-19.
I-TECH Study of 10X Ivermectin Dose to Prevent Severe COVID-19
Ivermectin proponents like the FLCCC have claimed that ivermectin works best as a prophylaxis or in early cases of COVID-19, preventing people from getting severe COVID-19.
Ivermectin’s efficacy as a prophylaxis was already dealt a fatal blow, when the FLCCC’s cheerleader himself – Dr. Pierre Kory and his daughter got sick from COVID-19 despite being on the I-MASK+ ivermectin protocol.
Keep in mind that the FLCCC only advocates taking one ivermectin tablet a week, which doubled after it failed to protect Dr. Kory from COVID-19.
The I-TECH (Ivermectin Treatment Efficacy in COVID-19 High-Risk Patients) Study aimed to address the other question – can ivermectin prevent COVID-19 patients from developing severe disease?
Registered in the Clinical Trials database as NCT04920942, it was a multi-centre open-label randomised controlled trial of 490 patients using 5X the dose of ivermectin recommended by the FLCCC.
- patients who were 50 years and above, with co-morbidities were selected because they are most likely to develop severe COVID-19
- patients had to be hospitalised, with Stage 2 / 3 (mild to moderate) COVID-19
- patients were randomised at a 1:1 ratio to :
a) IVM group receiving ivermectin + standard of care
b) SOC group receiving only standard of care
- IVM group patients received 2X the standard dose of ivermectin (0.4 mg/kg/day) for 5 days – 5X higher than recommended by the FLCCC
I-TECH Study : 10X Ivermectin Can’t Prevent Severe Covid-19!
After follow-up ended on 25 October 2021, the team released a preliminary report in November 2021, before it was peer-reviewed and published in the Journal of the American Medical Association (JAMA) on 18 February 2022.
I read through the I-TECH paper published in JAMA Internal Medicine, and summarised their key findings in the tables below.
No Significant Difference In Clinical Outcomes
There was little difference between the two groups. In other words – ivermectin offered no clinical benefit to those who took it, even at 2X the usual dose.
Keep in mind that even COVID-19 vaccines have to show a minimum of 50% efficacy. That minimum level of efficacy was not demonstrated in the I-TECH trial, even at 5X the dose recommended by the FLCCC.
|Progress to severe COVID-19||21.6%||17.3%||0.25, not significant|
|Time to severe COVID-19 (mean)||3.2 days||2.9 days||0.51, not significant|
|Patients requiring ventilation||1.7%||4.0%||0.17, not significant|
|Patients admitted to ICU||2.5%||3.2%||0.79, not significant|
|In-hospital mortality||1.2%||4.0%||0.09, not significant|
|Length of hospital stay (mean)||7.7 days||7.3 days||0.38, not significant|
|Total symptom resolution (day 5)||51.3%||53.0%||0.72, not significant|
|Normal chest radiography (day 5)||25.6%||24.9%||0.92, not significant|
Ivermectin proponents are pointing out that more people died in the control group than with ivermectin. However, the truth is that 4 deaths in the control group were from nosocomial sepsis, not COVID-19.
If we adjust for that, this is what the true comparison of COVID-19 mortality would be like – even less significant.
Ivermectin proponents are also complaining that the study did not properly match the two groups, while ignoring the inconvenient fact that the ivermectin group has almost twice as many people who were fully-vaccinated than the control group.
That alone would have greatly improved the ivermectin group’s chances of warding off serious COVID-19, and death. And yet, the ivermectin group did not show any significant advantage over the control group.
In fact, if the study authors perform a sub-group analysis with equal number of fully-vaccinated individuals, it’s likely that the mortality rate will be similar.
Significantly More Side Effects
The study also revealed that the ivermectin group suffered significantly more non-serious side effects, particularly diarrhoea.
The ivermectin group also experienced significantly more serious side effects :
- 4.3X more serious side effects reported
- 3.1X more Grade 3 side effects than the standard of care group
- 5.3X more Grade 4 side effects than the standard of care group
Two patients who received ivermectin, for example, suffered heart attacks during the short trial period.
|Non-Serious Side Effects||15.8%||4.8%||+ 3.3X|
|Serious Side Effects
– Myocardial infarction
– Arterial injury
– Severe Anaemia
– Hypovolemic Shock
|CTCAE Grade 1||9.5%||2.8%||+ 4X|
|CTCAE Grade 2||3.3%||1.2%||+ 2.8X|
|CTCAE Grade 3||2.5%||0.8%||+ 3.1X|
|CTCAE Grade 4||2.1%||0.4%||+ 5.3X|
Summary : 10X Ivermectin Does Not Prevent Severe COVID-19
I should also point out that I-TECH was an OPEN LABEL trial, which means participants are aware and consent to receiving ivermectin.
That alone would skew the results in favour of the ivermectin group, as participants would benefit from the placebo effect.
Yet the results show that ivermectin did not prevent those who received it from progressing to severe COVID-19, despite taking 5X the dose recommended by the FLCCC, and 10X the standard dose.
On the other hand, 1 in 59 patients who took ivermectin for just 5 days reported serious side effects.
Based on the I-TECH trial results, there can be no doubt – ivermectin cannot protect patients from developing severe COVID-19, even at 10X the standard dose.
So ask yourself – how then can ivermectin work at 2X the dose once a week, as recommended by proponents like the FLCCC?
- Is There RM300 Seat Belt Fine On PLUS Highway?
- Reiner Fuellmich COVID-19 Grand Jury Debunked!
- Did Ukrainians Just Protest Against US Interference In Kyiv?!
- Test + Quarantine SOP For Travel To Malaysia, From 1 April!
- Test + Quarantine SOP For Travel To Malaysia, Until 31 March!
If you like our work, please support us by visiting our sponsors, or donating to our fund. Thank you!